Retro Biosciences Achieves $1.8 Billion Valuation in Latest Funding Round
STAT+: Longevity startup Retro Biosciences says latest fundraising values it at $1.8 billion
Image: Stat
Retro Biosciences, a longevity startup supported by OpenAI CEO Sam Altman, has secured funding that values the company at $1.8 billion. The startup aims to extend human lifespan by 10 healthy years through innovative therapies, including a clinical trial for an Alzheimer’s treatment.
- 01Retro Biosciences is focused on extending human lifespan by 10 years through various technologies.
- 02The startup is currently conducting its first clinical trial on a pill aimed at enhancing the clearance of protein aggregates in Alzheimer's patients.
- 03CEO Joe Betts-LaCroix reported positive progress in the trial, stating no dose-limiting toxicities have been observed.
- 04Data from the ongoing clinical trial is expected to be released around August.
- 05The company employs in vivo gene therapies and cell replacement therapies as part of its approach.
Advertisement
In-Article Ad
Retro Biosciences, a longevity startup backed by OpenAI CEO Sam Altman, has announced a new funding round that values the company at $1.8 billion. The startup's mission is to add 10 healthy years to human lifespan through innovative technologies. Currently, Retro is conducting its first clinical trial, which tests a pill designed to improve the body's ability to clear protein aggregates in patients with Alzheimer’s disease. CEO Joe Betts-LaCroix shared at STAT’s Breakthrough Summit West that the trial is progressing well, with no dose-limiting toxicities reported. He anticipates that data from this trial will be available around August.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you believe longevity startups can significantly extend human lifespan?
Connecting to poll...
More about Retro Biosciences
Read the original article
Visit the source for the complete story.